Artificial Intelligence driven personalized treatments is the fastest growing segment fueling the growth of T-cell Lymphoma market
 |
| T-cell Lymphoma Market |
The
global T-cell Lymphoma Market is estimated to be valued at US$ 1961.64 Mn in
2023 and is expected to exhibit a CAGR
of 9.8% over the forecast period 2023 to 2030, as highlighted in a new
report published by Coherent Market Insights.
Market Overview:
T-cell lymphoma is a type of cancer that affects lymphocytes called T cells
in the immune system. The treatment options available in the market include
chemotherapy, radiation therapy, stem cell transplantation, targeted therapy
and others. These treatment help in killing or slowing the growth of cancer
cells in the body.
Market key trends:
Artificial intelligence is being used in developing personalized treatments
for cancer. Through machine learning algorithms, AI analyzes a patient's
genetic information and determines the most suitable and effective treatment
plan. It also helps in monitoring the disease progression and modifying
treatment accordingly. Researchers are working on developing AI powered tools
that can quickly analyze cell images obtained through microscopy and identify
affected cells. This will help achieve faster and more accurate diagnosis. AI
is also being utilized to develop customized drug formulations and doses best
suited for individual patients. Pharmaceutical companies are investing in AI to
accelerate drug discovery and clinical trials processes.
Segment Analysis
T-cell
Lymphoma market size can be segmented based on type, treatment,
end-user and geography. Based on type, the market is segmented into peripheral
T-cell lymphoma, cutaneous T-cell lymphoma, anaplastic large cell lymphoma and
others. Among them, peripheral T-cell lymphoma dominates the market as it is
the most common type of mature T-cell lymphoma, representing about 10% to 15%
of all non-Hodgkin lymphoma cases in the United States.
Key Takeaways
The global T-cell Lymphoma market is expected to witness high growth,
exhibiting CAGR of 9.8% over the forecast period, due to increasing prevalence
of T-cell lymphoma worldwide.
Regional analysis - North America dominates the global T-cell Lymphoma market
owing to increasing cases of lymphoma in the region. Europe accounts for the
second largest share in the market due to presence of major players in
countries like Germany, UK and others. Asia Pacific is expected witness highest
growth rate due to rising healthcare expenditure and growing awareness about
lymphoma treatments in emerging economies like China and India.
Key players operating in the T-cell Lymphoma market are F. Hoffmann-La Roche
Ltd, Biocryst Pharmaceuticals Inc., Bristol-Myers Squibb Company, Kyowa Kirin
Co., Ltd., Genmab A/S, Seagen Inc., GlaxoSmithKline plc., Johnson and Johnson
Private Limited, Elorac, Acrotech Biopharma, Merck and Co. Inc., Novartis AG,
SHIONOGI & Co., Ltd., Spectrum Pharmaceuticals Inc., and Bausch Health
Companies Inc. Key players are focusing on launching novel therapies to expand
their market share. For instance, in 2021 Bausch Health Companies Inc. received
FDA approval for Zeposia for treatment of T-cell lymphoma.
For
more insights, read - https://www.newsstatix.com/t-cell-lymphoma-market-share-size-outlook-and-opportunity-analysis-2023-2030/
Comments
Post a Comment